Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza Drops Its Bid For Patheon

by Rick Mullin
October 26, 2009 | A version of this story appeared in Volume 87, Issue 43

Lonza has withdrawn its bid to acquire Patheon, a Canadian contract manufacturer of finished dosage pharmaceuticals. The Swiss firm cites various reasons, including the rejection of its bid, valued at $460 million, by JLL Patheon Holdings, a group of investors that holds 57% of the Canadian firm’s voting shares. Lonza’s acquisition of Patheon would have extended its contract services, now centered on the manufacture of active pharmaceutical ingredients, to final formulation. According to Lonza, it is still interested in adding formulation services to its offerings.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.